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p5RHH nanoparticle-mediated 
delivery of AXL siRNA inhibits 
metastasis of ovarian and uterine 
cancer cells in mouse xenografts
Kathryn A. Mills1,2, Jeanne M. Quinn1, S. Tanner Roach1, Marguerite Palisoul1,2, Mai Nguyen1, 
Hollie Noia1, Lei Guo1, Jawad Fazal3, David G. Mutch2, Samuel A. Wickline3, Hua Pan3 & 
Katherine C. Fuh1,2
Ovarian and uterine serous cancers are extremely lethal diseases that often present at an advanced 
stage. The late-stage diagnosis of these patients results in the metastasis of their cancers throughout 
the peritoneal cavity leading to death. Improving survival for these patients will require identifying 
therapeutic targets, strategies to target them, and means to deliver therapies to the tumors. One 
therapeutic target is the protein AXL, which has been shown to be involved in metastasis in both 
ovarian and uterine cancer. An effective way to target AXL is to silence its expression with small 
interfering RNA (siRNA). We investigate the ability of the novel siRNA delivery platform, p5RHH, 
to deliver anti-AXL siRNA (siAXL) to tumor cells both in vitro and in vivo as well as examine the 
phenotypic effects of this siRNA interference. First, we present in vitro assays showing p5RHH-siAXL 
treatment reduces invasion and migration ability of ovarian and uterine cancer cells. Second, we show 
p5RHH nanoparticles target to tumor cells in vivo. Finally, we demonstrate p5RHH-siAXL treatment 
reduces metastasis in a uterine cancer mouse xenograft model, without causing an obvious toxicity. 
Collectively, these findings suggest that this novel therapy shows promise in the treatment of ovarian 
and uterine cancer patients.
Ovarian cancer is the fifth leading cause of cancer death in women, and the five-year survival rate for ovarian can-
cer patients is less than 50%1. Because the symptoms of ovarian cancer (e.g., bloating, gas, nausea, and abdominal 
discomfort) are common with other diseases, most ovarian cancer patients present at an advanced stage2, at which 
point the cancer has already metastasized throughout the peritoneal space. Like ovarian cancer, high-grade uter-
ine serous cancer is highly lethal, accounting for 40% of uterine cancer deaths3,4. Improving survival for ovarian 
and uterine cancer patients will require identifying therapeutic targets, strategies to target them, and means to 
deliver therapies to the tumors.
One candidate target protein involved in ovarian and uterine cancer metastasis is the TAM receptor tyrosine 
kinase family member AXL. Upon binding to its ligand, Gas6, AXL can activate several signal transduction path-
ways involved in cancer5–11. Recently, we found that high AXL expression in tumors correlates with poor survival 
in patients with high-grade uterine cancer. Additionally, AXL inhibition in uterine cancer cells decreased in vitro 
migration and invasion and in vivo metastatic potential in a mouse xenograft model12. AXL inhibition similarly 
prevents in vitro and in vivo invasion and migration of many other cancer types including brain, lung, and ovarian 
cancer12–22. Thus, targeting AXL could combat metastasis in both ovarian and uterine cancer.
One way to target AXL is to silence its expression with small interfering RNA (siRNA), and several nanoparti-
cle systems have been developed to deliver siRNAs into cells. Although nanoparticles formed with cationic lipids 
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and polymers effectively deliver siRNAs in vivo, these nanoparticle systems have not been used clinically because 
of potential toxicities caused by their propensity to aggregate with proteins in the serum23–27. An siRNA delivery 
system that can overcome these limitations is needed.
One promising nanoparticle siRNA delivery system, p5RHH28, was developed by selectively modifying a nat-
ural amphipathic cationic peptide: melittin29–31. Moreover, its c-terminal sequence has been altered with addi-
tion of multiple arginine and histidine residues for peptide-nucleotide interaction and pH sensing28,32. For the 
cytoplasmic siRNA delivery, p5RHH carries siRNA through peptide-nucleotide interaction enabled nanoparticle 
formation and the nanoparticles enter cells via endocytosis28. In the late endosome, p5RHH releases siRNA upon 
protonation of the histidine residues during the acidification of the endosome. Once p5RHH and siRNA are 
separated, the local high concentration of p5RHH in the endosome facilitates pore-formation in the endosomal 
membrane, allowing the siRNA to escape into the cytoplasm28,32. In the circulation, the siRNA-peptide complex is 
protected from destruction, and the peptide itself is at insufficient concentration to effect off-target membranoly-
sis. Levels of administrated p5RHH is also noted to be well below the IC50, which it beween 200–400 μM. In the 
case of p5RHH, a trigger for pH-mediated particle disassembly with concurrent siRNA release is by endosomal 
acidification with concurrent siRNA release. The release of free p5RHH also leads to endosomal escape, which 
can only occur once concentrated in an endosome. This is a unique characteristic of p5RHH/siRNA nanoparticles 
to efficiently coordinate peptide and siRNA release within endosomal escape.
In vitro, p5RHH nanoparticles were used to deliver siRNAs to multiple cell types, including melanoma cells, 
endothelial cells, and macrophages for knockdown of different mRNAs, such as p65, p100, JNK2, and STAT332. 
In vivo, p5RHH–siRNA nanoparticles were shown to decrease expression of the p65 subunit of NF-kappa-B in 
a mouse model of rheumatoid arthritis, leading to decreased ankle thickness and arthritic scores33. These nano-
particles were hypothesized to localize to arthritic joints by escaping from inflamed and leaky vasculature in the 
joints. A similar mechanism, the endothelial permeability and retention effect, allows nanoparticles to localize 
to cancer cells by escaping from inflamed and leaky vasculature in tumors. Given the ability of p5RHH to deliver 
siRNAs to tumor cells in vitro and to arthritic joints in vivo, as well as the similarities between arthritic joints 
and the tumor environment, we hypothesized that p5RHH could be used to deliver AXL-targeting siRNAs to 
high-grade ovarian and uterine serous tumor for potential clinical translation.
Results
p5RHH-siAXL nanoparticles decrease invasion and migration of uterine and ovarian cancer 
cells. To determine whether p5RHH nanoparticles could decrease migration and invasion, we first asked 
whether they could decrease AXL expression in uterine and ovarian serous cancer cells. We first confirmed 
knock down of AXL was maintained for as long as 96 hours after treatment with p5RHH-siAXL nanoparticles 
(Supplementary Fig. S5). We next treated ARK1 uterine serous cancer cells and OVCAR8 ovarian cancer cells with 
buffer, AXL siRNA (siAXL) alone, p5RHH-scrambled siRNA nanoparticles (p5RHH-siControl), or p5RHH-si-
AXL siRNA nanoparticles and evaluated protein expression after 72 hours. Treatment with p5RHH-siAXL siRNA 
nanoparticles led to a decrease in expression of AXL and phospho-AXL in both cell lines (Fig. 1A). Additionally, 
quantitative RT-PCR demonstrated that AXL RNA expression was significantly decreased by p5RHH-siAXL 
siRNA nanoparticles treatment in both cell lines (Fig. 1B). We next tested the p5RHH-siRNA-treated ARK1 and 
OVCAR8 cells in matrigel invasion and migration assays. In both cell lines, p5RHH-siAXL siRNA nanoparticles 
treated cells were significantly less invasive than those in the vehicle, siAXL only, and p5RHH-siControl nanopar-
ticles treatment conditions (Fig. 2A,B). In addition, these assays were performed in ARK1 cells with constitutive 
short hairpin knockdown of AXL or a scrambled sequence. In cell lines with a scrambled sequence, treatment 
with p5RHH-siAXL particles resulted in even less invasion than cells harboring shAXL mutation (Supplementary 
Fig. S3A,B).
p5RHH-siRNA nanoparticles localize to tumor cells in vivo. To assess the in vivo utility of 
p5RHH-siAXL nanoparticles, we first wanted to determine whether or not p5RHH would localize to tumors as 
it did to inflamed joints in the mouse model of arthritis33, and we wanted to identify the best delivery method. 
To answer these questions, we injected ARK1 and OVCAR8 cells into NOD/SCID and NU/FOX mice, respec-
tively. After tumors had established, we injected mice either intraperitoneally (IP) or intravenously (IV) with 
p5RHH-siControl nanoparticles, in which siControl siRNA was covalently conjugated with the fluorescent probe 
Quasar 705. Fluorescent images taken 24 hours later revealed that for both tumor cell types, the IP-injected mice 
had more fluorescent signal in the peritoneal cavity than did the IV-injected mice (Fig. 3A). In addition, ex 
vivo imaging of tumors of both types revealed that a greater quantity of IP-injected nanoparticles compared to 
IV-injected nanoparticles localized to tumors (Fig. 3B,C). Finally, we found that, following both injection routes, 
the fluorescent probe was localized intracellularly in tumors (Fig. 3D), and the tumors from the IP-injected mice 
had more intracellular fluorescence than those from IV-injected mice. Thus, we conclude that the p5RHH nano-
particles localize to and release their contents into tumor cells and that IP administration is more effective than IV 
administration. Moreover, in this specific pathological condition, it is feasible for IP-administration.
p5RHH-siAXL treatment significantly reduces in vivo metastasis and is non-toxic. Given that 
p5RHH-siRNA nanoparticles could localize to tumors and that p5RHH-siAXL treatment in vitro decreases inva-
sion and migration, we investigated whether p5RHH-siAXL treatment could reduce in vivo metastasis of ARK1 
cells. After two weeks of treatment, mice that received p5RHH-siAXL nanoparticle treatment had significantly 
fewer intraperitoneal tumor nodules (8.8 vs. 17.6) and lower overall tumor mass (0.016 g vs. 0.048 g) than mice 
that received p5RHH-siControl nanoparticles (Fig. 4A,B). We found a similarly lower number of intraperito-
neal OVCAR8 tumor nodules in mice that received p5RHH-siAXL nanoparticles than in those that received 
p5RHH-siControl nanoparticles (Supplementary Fig. S1). In addition, quantitative RT-PCR demonstrated that 
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AXL RNA expression was significantly decreased in tumors treated with p5RHH-siAXL nanoparticles com-
pared to p5RHH-siControl nanoparticle treated tumors (Fig. 4C). In addition, tumors from mice that received 
p5RHH-siAXL had decreased levels of AXL IHC expression compared to p5RHH-siControl and vehicle mice 
(Fig. 4D). In addition, analysis of mouse tumors showed significantly decreased markers of metastasis (Matrix 
metallopeptidase 2 and Matrix metallopeptidase 3) in tumors from mice treated with p5RHH-siAXL nanoparti-
cles compared to control (Supplementary Fig. S4). Together, these results show p5RHH-siAXL treatment reduces 
in vivo tumor metastasis.
To determine whether p5RHH-siAXL nanoparticle treatment caused any hematologic toxicity, we performed 
blood analyses on samples collected from the mice. We detected no significant difference in white blood cell, red 
blood cell, hemoglobin, or platelet counts between buffer-, p5RHH-siControl nanoparticle-, and p5RHH-siAXL 
nanoparticle-treated mice bearing ARK1 or OVCAR8 cells (Table 1). Furthermore, pathologic analysis of major 
organs revealed no histological differences between the treatment groups (Fig. 5A). Together, these findings indi-
cate that p5RHH-siAXL nanoparticle treatment has preferable safety profile.
Discussion
High-grade serous ovarian and uterine cancers are extremely lethal34,35. Although many patients respond to initial 
chemotherapy, most will eventually relapse and die because of metastatic disease3,4. Recently, AXL was shown to 
have a role in ovarian and uterine cancer metastasis, making it a therapeutic target to combat metastasis in these 
cancers. Here, we present evidence that p5RHH-siAXL nanoparticles inhibit AXL expression both in vitro and in 
vivo in ovarian and uterine cancer models. Additionally, in in vitro assays, p5RHH-siAXL nanoparticle treatment 
reduced invasion and migration ability of ovarian and uterine cancer cells. Finally, p5RHH-siAXL nanoparticles 
target to tumor cells and reduce metastasis without causing any obvious toxicity. Additionally, we focused on 
p5RHH-siControl and p5RHH-siAXL rather than p5RHH alone for toxicity given that p5RHH is only released 
once inside the endosome. Thus, there is no activity of p5RHH alone unless inside the endosome36. p5RHH exists 
in nanoparticle form only and is only released in free form once inside the endosome. Without siRNA compo-
nents, there would be no nanoparticle and the siRNA would be subject to immediate effects of RNAases in cir-
culation and the peptide rapidly cleared by the kidney, and thus p5RHH alone exerts no therapeutic activity. The 
peptide itself, being bound in the nanoparticle, does not circulate freely as it requires a low pH (<5) to cause the 
Figure 1. p5RHH nanoparticles effectively inhibit AXL and functional AXL. (A) Western blot analysis of 
phospho-AXL and AXL expression in ARK1 and OVCAR8 cell lines treated with vehicle, siAXL only, p5RHH-
siControl, or p5RHH-siAXL. Actin is shown as a loading control. (B) qRT-PCR was performed on cells treated 
with p5RHH-siControl or p5RHH-siAXL and AXL mRNA expression was assessed. Data are represented 
as mean +/− SD and asterisks indicate significant decrease in expression compared to p5RHH-siControl as 
determined by the student’s t-test. ****P < 0.0001.
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nanoparticle to disaggregate28. Such conditions exist inside the endosome as previously published. Accordingly, 
there is no opportunity for p5RHH to exist in free form and cause toxicity. Once the nanoparticles are disaggre-
gated in the endosome upon lowering of pH, the peptide is released causing endosomolysis. The peptide, now in 
free form, exerts no toxicity on any tissues or organs33,37,38.
In previous work, we showed that silencing AXL with short hairpin RNA decreased migration and invasion in 
vitro and reduced in vivo metastatic potential of uterine cancer12. However, short hairpin RNAs must be delivered 
via a viral vector, which can integrate into DNA and increase the risk of new mutations39. In contrast, p5RHH 
nanoparticles show promise as a clinically translatable option for safely silencing gene expression.
Our data indicate that p5RHH-siAXL safely targets tumors without causing off-target toxicities. The full body 
fluorescent images show that the nanoparticles were limited to the peritoneal cavity regardless of administration 
route (IV or IP) and did not accumulate in any upper respiratory organs. The only major organs to show fluores-
cence signal in the ex vivo images were the kidney and liver. The renal fluorescence was expected because p5RHH 
is excreted through the renal system. Although fluorescence signal was present in the liver, pathologic analysis 
revealed no signs of tissue damage. Additionally, the hematologic data demonstrate no difference among the 
treatment groups. Collectively, these findings suggest that this therapy shows promise in the treatment of ovarian 
and uterine cancer patients.
Figure 2. p5RHH-siAXL nanoparticles decrease in vitro invasion. Representative images of matrigel invasion 
assay of (A) OVCAR8 and (B) ARK1 cells treated with vehicle, siAXL, p5RHH-siControl, or p5RHH-siAXL. 
Graphs depict the number of invaded cells at 48 hours. Data are represented as mean +/− SD. ***P < 0.001, 
****P < 0.0001 by student’s t-test.
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Methods
Cell Lines and Conditions. The uterine serous cancer cell line ARK1 was provided by Shi-Wen Jiang 
(Mercer University School of Medicine, Savannah, GA, USA), and the high grade serous ovarian cancer cell line 
OVCAR8 was purchased from the National Cancer Institute-Frederick DCTD tumor cell line repository. Cells 
were maintained in RPMI (Sigma, St. Louis, MO) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS) (Sigma, St. Louis, MO) and 1% penicillin and streptomycin (Invitrogen, Carlsbad, CA) at 37 °C in a 5% 
Figure 3. p5RHH-siControl-Quasar 705 nanoparticles localize to tumor cells in mouse xenograft models. 
Representative (A) in vivo and (B) ex vivo biodistribution images of IV- or IP-injected p5RHH-siControl-
Quasar 705 probed nanoparticles in ARK1 and OVCAR8 tumor-bearing mice. (C) Quantitation of tumor 
fluorescence in mice injected with p5RHH-siControl-Quasar 705 relative to tumor fluorescence in mice 
injected with vehicle. (D) Representative images of ARK1 and OVCAR8 tumor cells in mice. Blue, nuclear dye 
DAPI; pink, Quasar 705 fluorescence. Data are represented as mean +/− SD. ***P < 0.001 by unpaired t-test.
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CO2 incubator. For p5RHH treatment, cells were incubated in FBS-containing media without antibiotics for one 
day, then incubated in FBS-free, antibiotic-free media for 6 hours during incubation with p5RHH nanoparticles.
Preparation of p5RHH nanoparticles. p5RHH peptides were prepared and stored as previously 
described32. For in vitro use, p5RHH-siRNA nanoparticles were constructed by mixing 1 µL of 20 mM p5RHH 
peptide with 10 µL of 20 µM siRNA in 389 µL of serum-free, antibiotic-free RPMI (Sigma, St. Louis, MO). The 
mixture was incubated at 37 °C for 40 minutes before use. Human AXL siRNA (ON-TARGETplus SMART pool 
#L-003104-00-0005) and siControl (ON-TARGETplus Non-targeting pool #D-001810-10-05) (Dharmacon, 
Figure 4. Treatment with p5RHH-siAXL significantly reduces metastasis of ARK1 xenografts. Graphs 
depicting the (A) number of peritoneal tumor nodules and (B) total tumor weight per mouse treated with either 
p5RHH-siControl (n = 5) or p5RHH-siAXL (n = 5). (C) qRT-PCR was performed on tumors treated with 
p5RHH-siControl or p5RHH-siAXL and AXL mRNA expression was assessed. (D) Representative images of 
AXL and ki67 immunohistochemistry of tumor samples from vehicle, p5RHH-siControl, or p5RHH-siAXL 
mice at 40X magnification. Data are represented as mean +/− SD. *P < 0.05, **P < 0.01, ***P < 0.001 by 
unpaired t-test.
7Scientific RepoRts |          (2019) 9:4762  | https://doi.org/10.1038/s41598-019-41122-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
Lafayette, CO) were dissolved at 20 μM in molecular grade water (Mediatech, Manassas, VA) and stored at −20 °C 
before use.
For in vivo use, p5RHH-siRNA nanoparticles were constructed by mixing 4 µl of 100 mM p5RHH 
peptide with 8 µL of 100 µM siRNA in 188 µl of phosphate buffered saline (PBS) with Ca2+ and Mg2+ 
(Sigma, St. Louis, MO) per mouse. The mixture was then incubated on ice for 8 minutes and mixed with 
0.8 µl of 0.2 g/ml mouse albumin (Sigma, St. Louis, MO) reconstituted in molecular grade water. Human 
AXL siRNA (Sense: 5′–ACAGCGAGAUUUAUGACUAUU; 5′-GGUA CCGGCUGGCGUAUCAUU; 
5′-GACGAAAUCCUCUAUGUCAUU; 5′-GAAGGAGACCCGUUAUGGAUU) for in vivo use was created as 
a custom product (Dharmacon, Lafayette, CO) of four ON-TARTGET plus sequences against AXL reconstituted 
to 100 µM with 1x siRNA Buffer then pooled. In Vivo siControl (Dharmacon, Lafayette, CO) was reconstituted to 
100 µM in 1x siRNA Buffer.
Preparation of p5RHH-siSCRM-Quasar 705. Nanoparticle complexes were prepared by combining 
p5RHH and eGFP-Quasar 705-probed-siControl at 100:1 (Sigma, St. Louis, MO) in PBS supplemented with Ca2+ 
and Mg2+ (Sigma, St. Louis, MO). The mixture was incubated at 37 °C for 40 minutes.
p5RHH-siRNA Treatment. Twenty-four hours before transfection, ARK1 or OVCAR8 cells were plated 
in RPMI medium supplemented with 10% FBS without antibiotics. The nanoparticle solution was then added 
and cells were starved in antibiotic-free, FBS-free media. After 6 hours, cells were placed in RPMI with 10% heat 
inactivated FBS.
Western Blot Analysis. After 72 hours of exposure to specified treatment, cells were lysed in 9 M Urea, 
0.075 M Tris, pH 7.6. Protein concentration was determined by using the Bradford assay, and lysates were sub-
jected to reducing SDS/PAGE by standard methods. Western blots were incubated with primary antibodies against 
AXL (R&D Systems; 1:1000) and phospho-AXL (Cell Signaling; 1:500). To confirm equal protein loading, blots 
were probed with antibodies specific for β-actin (Sigma Aldrich; 1:3000). Horse-radish peroxidase-conjugated 
secondary antibodies were used to detect protein expression (Jackson ImmunoResearch, West Grove, PA) and 
chemiluminescence was measured on a ChemiDoc (Bio-Rad Laboratories).
cDNA Preparation and qPCR. After 72 hours of indicated treatment, total RNA was isolated from 
ARK1 and OVCAR8 by using the RNeasy Mini Kit (Qiagen). cDNA was made from 1 µg of RNA by using the 
ARK1 OVCAR8
Vehicle p5RHH-siControl p5RHH-siAXL Normal Range Vehicle p5RHH-siControl p5RHH-siAXL Normal Range
WBC (10^3/uL) 3.2 1.6 ± 0.1 5.0 ± 3.1 0.96–4.68 4.6 ± 1.3 1.7 ± 0.8 6.3 ± 1.8 1.42–10.25
RBC (10^6/uL) 8.1 8.6 ± 0.3 8.7 ± 0.1 8.21–10.48 9.4 ± 0.1 10.3 ± 0.1 9.7 ± 0.1 6.82–10.53
HGB (g/dL) 13.1 12.8 ± 0.5 13.0 ± 0.1 12.1–17.6 14.4 ± 0.2 15.1 ± 0.6 14.0 ± 0.1 10.9–15.9
PLAT (10^3/uL) 830 1233.5 ± 12.5 1048 ± 178 651–1878 859.5 ± 58.5 949.5 ± 166.5 723.5 ± 31.5 376–1796
Table 1. p5RHH-siAXL complete blood count. *There were no difference between means found by one-way 
ANOVA analysis. Complete blood count table of blood samples from ARK1 and OVCAR8 mice treated with 
vehicle, p5RHH-siControl, or p5RHH-siAXL. Data are represented as mean +/− SD and significance was 
determined by one-way ANOVA.
Figure 5. Histological evaluation of major organs. (A) Representative images of hematoxylin and eosin-stained 
kidney and liver from OVCAR8 xenograft-bearing mice.
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SuperScript IV system (Thermo Fisher Scientific) according to the manufacturer’s directions. Applied Biosystems 
7500 detection system and SYBR-green master mix (Thermo Fisher Scientific) were used to perform qPCR. 
mRNA expression was normalized to 18 S ribosomal RNA, and fold change was calculated by using the 2−ΔΔCt 
method. Primer sequences for AXL were published previously17,40,41.
Transwell Invasion Assay. Cells were treated with p5RHH-siRNA for 48 hours, starved for 24 hours in 
RPMI with 1% FBS, and then used for invasion assays. The matrigel invasion assay was performed in Boyden 
transwell chamber according to the manufacturer’s protocol with matrigel (Corning) diluted to 0.5 mg/ml in 
PBS. Chemoattractant made of 20% FBS, 0.4 µL of 100 ng/mL GAS6 (R&D systems), and 5 µl of 1 mg/ml human 
fibronectin (Corning) was added to the bottom well. Cells were allowed 48 hours to invade. Invaded cells were 
fixed, stained, and counted in four different fields at 20x magnification. All experiments were performed in 
triplicate.
Immunohistochemistry. Major organs from mice were resected, fixed in fresh formalin for 48 hours, 
subjected to 10-minute washes in increasing ethanol concentration up to 70% ethanol, and then processed for 
paraffin embedding. Slides were deparaffinized in Xylene, gradually rehydrated in decreasing concentrations of 
ethanol followed by heat-induced antigen retrieval in sodium citrate, pH 6, for 8 minutes. Slides were probed 
with polyclonal goat anti-Human AXL antibody (R&D Systems; 1:40) at 4 °C overnight. Slides were then washed 
and incubated with HRP-conjugated secondary antibody (Vector Laboratories; 1:200). Antibody complexes 
were detected with 3,3′ – diaminobenzidine (Dakos), and slides were counter stained with Mayer’s Hematoxylin. 
Sections (5 µm) were mounted on glass microscope slides. Tissues from major organs were stained with hematox-
ylin and eosin (H&E) to identify any effects from treatment.
Murine Xenograft Studies. All procedures involving animals and their care were performed in accord-
ance with the guidelines of the American Association for Accreditation for Laboratory Animal Care and the 
U.S. Public Health Service Policy on Humane Care and Use of Laboratory Animals. All animal studies were also 
approved and supervised by the Washington University Institutional Animal Care and Use Committee in accord-
ance with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and NIH guidelines.
Cells were prepared in 0.2 ml of MgCl2 and CaCl2 supplemented PBS (Sigma), and 1 × 107 ARK1 and 5 × 106 
OVCAR8 cells were injected intraperitoneally into female 6–8-week-old NOD SCID (Jackson Laboratory) or 
NU/FOX (Charles River) mice, respectively. Mice were monitored for adverse events until sacrifice. Tumor sam-
ples were fixed in formalin and embedded in paraffin or snap frozen for further analysis.
Nanoparticle Localization Studies. ARK1 and OVCAR8 cells were injected into mice and allowed 36 
and 28 days, respectively, to establish tumors. Mice were fed Irradiated AIN-93M chow (Research Diets, New 
Brunswick, NJ). Vehicle control mice were injected with PBS supplemented with MgCl2 and CaCl2 both intraperi-
toneally and intravenously, and the treatment groups were injected either intraperitoneally or intravenously with 
p5RHH-eGFP-Quasar 705-probed-siControl nanoparticles. After 24 hours, the mice were imaged with the Pearl 
Trilogy Small Animal Imaging System (LI-COR Biosciences, Lincoln, NB). During in vivo imaging, mice were 
maintained under isoflurane inhalation anesthesia until sacrifice by both CO2 euthanasia and cervical dislocation. 
Before dissection and ex vivo tissue imaging mice were systemically perfused with PBS. Image acquisition settings 
were: excitation 685 nm, emission 720 nm, field of view 11.2 cm × 8.4 cm, exposure time 2 sec. For microscopic 
localization, tumor OCT blocks were cryosectioned (10 µm), mounted in mounting media (Cat#: H-1200, Vector 
Laboratories, Burlingame, CA), and imaged with an Olympus BX63 fluorescence microscope (Olympus, Center 
Valley, PA). All images were obtained at the same imaging acquisition conditions.
In vivo nanoparticle-mediated siRNA delivery. ARK1 and OVCAR8 cells were injected into mice and 
allowed to establish tumors for 6 days and 3 days, respectively. ARK1 xenograft mice models were injected intra-
peritoneally with p5RHH-siControl or p5RHH-siAXL. OVCAR8 xenograft models were injected intraperitone-
ally with either PBS, p5RHH-siControl, or p5RHH-siAXL. The p5RHH-siRNA intraperitoneal dosing regimen 
was determined by treating mice with increasing ratios of p5RHH to siAXL with a final ratio of 100:1. Final 
therapeutic dosing cycles were 3 days of treatment followed by 1 day off for a span of 2 weeks. Mice were then 
sacrificed and dissected.
Statistical analyses. Graphpad Prism 7.03 software was used for statistical analyses. Two-tailed unpaired 
Student’s t tests and one-way ANOVA were performed to analyze statistical differences between groups. P < 0.05 
was considered statistically significant.
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